These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 9816008)

  • 21. Comparative analysis of the priming effect of human interferon-gamma, -alpha, and -beta on synergism with muramyl dipeptide analog for anti-tumor expression of human blood monocytes.
    Utsugi T; Sone S
    J Immunol; 1986 Feb; 136(3):1117-22. PubMed ID: 3079797
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro synergic effect of interferon gamma combined with liposomes containing muramyl tripeptide on human monocyte cytotoxicity against fresh allogeneic and autologous tumor cells.
    Galligioni E; Santarosa M; Favaro D; Spada A; Talamini R; Quaia M
    Tumori; 1994 Oct; 80(5):385-91. PubMed ID: 7839471
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Potent in situ activation of murine lung macrophages and therapy of melanoma metastases by systemic administration of liposomes containing muramyltripeptide phosphatidylethanolamine and interferon gamma.
    Fidler IJ; Fan D; Ichinose Y
    Invasion Metastasis; 1989; 9(2):75-88. PubMed ID: 2496047
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Induction of tumoricidal properties in human monocytes by synergism between interferon-gamma and liposome-entrapped muramyl tripeptide].
    Utsugi T; Sone S; Tandon P; Ogawara M; Shimizu E; Nii A; Nakanishi M; Shono M; Ogura T
    Gan To Kagaku Ryoho; 1986 Oct; 13(11):3161-8. PubMed ID: 3096216
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intravesical liposomal muramyl tripeptide phosphatidylethanolamine treatment of human bladder carcinoma growing in nude mice.
    Dinney CP; Tanguay S; Bucana CD; Eve BY; Fidler IJ
    J Interferon Cytokine Res; 1995 Jun; 15(6):585-92. PubMed ID: 7553228
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The schistosomulicidal activity and the production of IL-1 and TNF-alpha by peritoneal macrophages from infected mice and their potentiation by muramyl tripeptide-phosphatidyl ethanolamine (MTP-PE) treatment.
    Seger M; Gold D; Lengy J; Pauli H; Keisari Y
    Parasite Immunol; 1993 Jun; 15(6):339-47. PubMed ID: 8361776
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combination therapy with ifosfamide and liposome-encapsulated muramyl tripeptide: tolerability, toxicity, and immune stimulation.
    Kleinerman ES; Meyers PA; Raymond AK; Gano JB; Jia SF; Jaffe N
    J Immunother Emphasis Tumor Immunol; 1995 Apr; 17(3):181-93. PubMed ID: 7613644
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative interaction of free and liposome-encapsulated nor-muramyl dipeptide or muramyl tripeptide phosphatidylethanolamine (3H-labelled) with human blood monocytes.
    Fogler WE; Fidler IJ
    Int J Immunopharmacol; 1987; 9(2):141-50. PubMed ID: 3583507
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A dried preparation of liposomes containing muramyl tripeptide phosphatidylethanolamine as a potent activator of human blood monocytes to the antitumor state.
    Sone S; Utsugi T; Tandon P; Ogawara M
    Cancer Immunol Immunother; 1986; 22(3):191-6. PubMed ID: 3731204
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interleukin-6 induction by a muramyltripeptide derivative in cancer patients.
    Frost H; Murray JL; Chaudri HA; Van Damme J
    J Biol Response Mod; 1990 Apr; 9(2):160-6. PubMed ID: 2341859
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine adjuvant immunotherapy for splenic hemangiosarcoma in the dog: a randomized multi-institutional clinical trial.
    Vail DM; MacEwen EG; Kurzman ID; Dubielzig RR; Helfand SC; Kisseberth WC; London CA; Obradovich JE; Madewell BR; Rodriguez CO
    Clin Cancer Res; 1995 Oct; 1(10):1165-70. PubMed ID: 9815908
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase II study of liposomal muramyl tripeptide phosphatidylethanolamine (MTP/PE) in advanced soft tissue sarcomas of the adult. An EORTC Soft Tissue and Bone Sarcoma Group study.
    Verweij J; Judson I; Steward W; Coleman R; Woll P; van Pottelsberghe C; van Glabbeke M; Mouridsen H
    Eur J Cancer; 1994; 30A(6):842-3. PubMed ID: 7917546
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [L-MTP-PE--a potential antineoplastic agent].
    Dzierzbicka K; Gozdowska M; Kołodziejczyk AM
    Postepy Hig Med Dosw; 1997; 51(2):227-36. PubMed ID: 9235567
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Liposome-encapsulated muramyl tripeptide up-regulates monocyte chemotactic and activating factor gene expression in human monocytes at the transcriptional and post-transcriptional levels.
    Asano T; Matsushima K; Kleinerman ES
    Cancer Immunol Immunother; 1994 Jan; 38(1):16-22. PubMed ID: 8299114
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Activation of tumoricidal properties in human blood monocytes by liposomes containing lipophilic muramyl tripeptide.
    Kleinerman ES; Erickson KL; Schroit AJ; Fogler WE; Fidler IJ
    Cancer Res; 1983 May; 43(5):2010-4. PubMed ID: 6831430
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pre- and postirradiation hemopoietic effects of liposomal muramyl tripeptide phosphatidylethanolamine (MTP-PE) administered to C57Bl/6 mice before irradiation.
    Macková NO; Fedorocko P
    Neoplasma; 1993; 40(6):379-85. PubMed ID: 8289971
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synergism between human recombinant gamma-interferon and muramyl dipeptide encapsulated in liposomes for activation of antitumor properties in human blood monocytes.
    Saiki I; Sone S; Fogler WE; Kleinerman ES; Lopez-Berestein G; Fidler IJ
    Cancer Res; 1985 Dec; 45(12 Pt 1):6188-93. PubMed ID: 3933823
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Liposomal muramyl tripeptide (CGP 19835A lipid) therapy for resectable melanoma in patients who were at high risk for relapse: an update.
    Gianan MA; Kleinerman ES
    Cancer Biother Radiopharm; 1998 Oct; 13(5):363-8. PubMed ID: 10851426
    [TBL] [Abstract][Full Text] [Related]  

  • 39. ImmTher, a lipophilic disaccharide derivative of muramyl dipeptide, up-regulates specific monocyte cytokine genes and activates monocyte-mediated tumoricidal activity.
    Worth LL; Jia SF; An T; Kleinerman ES
    Cancer Immunol Immunother; 1999 Sep; 48(6):312-20. PubMed ID: 10473806
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro and in vivo enhancement of canine pulmonary alveolar macrophage cytotoxic activity against canine osteosarcoma cells.
    Kurzman ID; Shi F; Vail DM; MacEwen EG
    Cancer Biother Radiopharm; 1999 Apr; 14(2):121-8. PubMed ID: 10850295
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.